Pontes J E, Choe B K, Rose N R, Pierce J M
J Urol. 1978 Jun;119(6):772-6. doi: 10.1016/s0022-5347(17)57629-6.
To evaluate the reliability of bone marrow acid phosphatase in the staging of prostatic carcinoma we analyzed 50 bone marrow samples collected at random from the hematology service at this hospital. The samples were assayed for acid phosphatase content by a colorimetric method using sodium thymolphthalein monophosphate as a substrate and by 2 immunochemical assays developed at our laboratory (counter immunoelectrophoresis and radioimmunoassay). We found a high percentage (61 per cent) of falsely positive results in patients with various hematological diseases without evidence of prostatic carcinoma by the colorimetric evaluation. All of these patients except 1 had negative immunochemical assay. Until a specific assay for prostatic acid phosphatase is developed for clinical use we caution the use of a single elevation of bone marrow acid phosphatase as a parameter of metastatic disease.
为评估骨髓酸性磷酸酶在前列腺癌分期中的可靠性，我们分析了从本院血液科随机采集的50份骨髓样本。采用以磷酸麝香草酚酞钠为底物的比色法以及我们实验室开发的2种免疫化学分析法（对流免疫电泳和放射免疫分析法）对样本的酸性磷酸酶含量进行测定。通过比色法评估，我们发现，在无前列腺癌证据的各种血液病患者中，假阳性结果的比例很高（61%）。除1例患者外，所有这些患者的免疫化学分析结果均为阴性。在开发出用于临床的前列腺酸性磷酸酶特异性检测方法之前，我们提醒，应谨慎将骨髓酸性磷酸酶单次升高用作转移性疾病的一个参数。
